Iroko announces Vivlodex availability

PHILADELPHIA — Iroko Pharmaceuticals on Tuesday announced the U.S. availability of its Vivlodex (meloxicam) capsules. The drug is a low-dose non-steroidal anti-inflammatory drug (NSAID) that was approved in October by the Food and Drug Administration to treat osteoarthritis pain. 

 

“We are pleased to introduce Vivlodex, our third low-dose SoluMatrix NSAID, and our second product for patients suffering from osteoarthritis pain," Iroko COO and president Lou Vollmer said. “Vivlodex now offers patients who are currently taking oral meloxicam an effective low-dose alternative that aligns with FDA prescribing recommendations to use the lowest effective dose of NSAIDs.”

 

Vivlodex, available in 5- and 10-mg dosage strength, uses a reduced particle size of its active ingredient, which can lead to a faster dissolution and absorption, the company said.